Xolair (omalizumab) - Roche, Novartis
Mast cell activation syndromes in clinical practice: diagnostic challenges, phenotypes, and real-life management. (PubMed, Postepy Dermatol Alergol) - Oct 18, 2026 - "Omalizumab may serve as an effective adjunct therapy in patients with persistent symptoms. A phenotype-based approach is warranted." 
Journal • Allergy • Cardiovascular • Immunology
http://www.ncbi.nlm.nih.gov/pubmed/42890065
 
Simge Erdem; Zeynep Yegin Katran
 
Oct 18, 2026
 
Prev Next